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Action of phosphorus on calcium release in isolated perfused rat tails. A
bone perfusion system using isolated rat tails was developed to study
the action of inorganic phosphorus (Pi) on calcium (Ca) release in bone.
Rats were either pre-labelled with 45Ca to study calcium removal from
bone or 45Ca was added to the perfusate to study Ca deposition into
bone. When perfusate Pi was increased from 3.5 to 5.25 mg/dl, a marked
inhibition of 45Ca release was demonstrated. 85Sr microspheres, used to
demonstrate differences in the flow of perfusate between bone and soft
tissue, showed that the Pi effect was not due to alterations in perfusate
flow to bone. Increasing the perfusate Pi concentration from 3.5 to 7
mg/dl did not increase 45Ca deposition into bone, nor did it affect
baseline or PTH-stimulated cyclic AMP production. The Pi effect was
inhibited by reducing the perfusate temperature to 4° C, by using an
anerobic perfusate, adding iodoacetate to the perfusate, and finally, by
pre-treating the rats with actinomycin D prior to the experiment. Thus,
in this model an increase in the Pi concentration of the perfusate inhibits
Ca release from bone but does not increase Ca uptake by bone. The
inhibitory effect appears to be dependent on normal cell metabolism.
Action du phospkore sur le relargage de calcium dàns des queues de
rats isolées perfusecs. lin système de perfusion osseuse utilisant des
queues de rats isolées a été developpe afin d'étudier l'action du
phosphore inorganique (Pi) sur Ic relargage du calcium (Ca) dans l'os.
Les rats recevaient an préalable du 45Ca pour étudier Ia disparition du
calcium osseux, ou bien du 45Ca ëtait ajouté au perfusat pour étudier Ic
dépôt de Ca dans l'os. Lorsque Ic Pi du perfusat était augmenté de 3,5 a
5,25 mg/dl, une inhibition marquee du relargage du 45Ca était démontra-
ble. Des microsphéres au 85Sr utilisées pour démontrer des differences
dans le debit de perfusion entre los et le tissu mou ont montré que
l'effet du Pi n'ètait pas d6 a des alterations du flux de perfusion osseux.
L'élévation de la concentration de Pi dans le perfusat de 3,5 a 7 mg/dl
n'a pas augmenté Ic dépôt de 45Ca dans l'os, ni n'a modiflé Ia
production d'AMP cyclique de base ou stimulée par Ia PTH. L'effet du
Pi était inhibé en réduisant Ia temperature du perfusat a 4° C, en
utilisant un perfusat anaerobique, en ajoutant de l'iodo acetate au
perfusat, et enfin en pré-traitant les rats avec de l'actinomycine D avant
l'experience. Ainsi, dans ce modèle, une augmentation de Ia concentra-
tion de Pi dans Ic perfusat inhibe le relargage de Ca a partir de los mais
n'augmente pas Ia captation de Ca par los. Cet effet inhibiteur semble
étre dépendant d'un métabolisme cellulaire normal.
Elevation of plasma phosphate has been shown to cause
hypocalcemia in many human situations [1—81 as well as in
several different animal experiments [9—14]. Although large
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amounts of phosphate administered acutely to humans will
cause soft tissue calcification, this is unlikely to be the only
mechanism by which phosphate causes hypocalcemia. Reiss et
al [6] have shown that slight elevations of serum inorganic
phosphorus are associated with a fall in total and ionized
calcium values and a rise in parathyroid hormone levels. This
phosphate-mediated fall in ionized calcium is the basis of the
theory proposed by Slatopoisky et al [14] to explain the
development of secondary hyperparathyroidism in renal failure.
Neither of these groups had an explanation for the hypocalce-
mic action of phosphorus. However, Hebert et al [7] gave
phosphorus infusions to humans suffering from various disor-
ders of calcium metabolism. They concluded that the serum
calcium fell because of calcium phosphate precipitation either
in bone or soft tissue. Eisenberg [4] reached a similar conclu-
sion from studies of patients with hypercalcemia of malignancy
who had been given phosphate intravenously.
In published animal studies there are conflicting reports. On
the one hand, Raisz and Niemann [15] showed that in vitro bone
resorption was inhibited when the phosphate concentration of
the medium was increased, whereas on the other hand, Fein-
blatt, Berlanger, and Rasmussen [131 concluded from in vivo
studies that phosphate lowered the plasma calcium by increas-
ing bone mineralization and possibly bone formation, although
bone resorption was not thought to be affected. Pechet et al [16]
also have presented evidence that phosphate causes hypocalce-
mia without suppressing the bone resorbing action of PTH and
finally, there is some in vitro evidence that an elevation of
phosphate concentration increases mineralization of embryonic
chick tibias maintained in tissue culture over a 4-day period
[17].
We decided to examine the mechanism of the effect of
phosphate on calcium movement in bone by observing the
release of pre-labelled 45Ca in a simple in vitro perfusion
system. In this particular model, phosphate was found to cause
inhibition of 45Ca release rather than to increase bone
mineralization.
Methods
Experimental model. The model used for these experiments
was an isolated rat tail perfused with a simple electrolyte
solution. Sprague-Dawley rats weighing about 160 to 170 g were
anesthetized with mactin 10 mg/100 g, heparinized, and the
ventral artery at the base of the tail was cannulated with PE 50
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Pressure
110 mm Hg
polyethylene tubing and secured with tissue glue. The tail was
perfused with a Krebs ringer bicarbonate buffer at 38° C as
shown in Figure 1. The flow rate was 50 to 52 mI/hr which
resulted in a pressure of 100 to 120 mm Hg. Before starting any
experiment, the tail was perfused for 2 hr so that the blood was
washed out completely. Thereafter, samples were collected
every 5 to 10 mm depending on the particular experiment.
During some initial 20 studies, a small amount of cardiogreen
was added to the perfusate at the end of the experiment;
subsequent examination of bone and soft tissue revealed ho-
mogenous green staining indicating that the tissues were being
perfused evenly. In less than 5% of the experiments leakage of
perfusate from the skin of the tail occurred; in these instances
this particular preparation was discarded. To demonstrate that
the tail remained viable during these experiments, we measured
the lactate concentration of the effluent collected every 10 mm
for 3 hr. It remained constant during this period. The mean
starting concentration was 6.3 1.2 mg/dl, and the mean
finishing concentration was 7.1 0.2 mg/dl, (N = 4).
An additional study to determine the viability of the tail
preparation was carried out. We used a perfusate containing
tritiated leucine 5 tCi/ml for an additional hour after a tail was
perfused for 3.5 hr. Sections then were prepared for autoradiog-
raphy to assess protein synthesis by the bone cells. Dense
collections of grains were seen in most osteoblasts present
along the trabecular surfaces. When simple undecalcified longi-
tudinal sections were examined for histological detail, it was
found that the vertebrae were composed of cortical bone with a
moderate amount of cancellous bone at the metaphysis which
ended in an area of growth cartilage. There was a small amount
of trabecular bone in the epiphysis.
In all experiments in the perfusion solution used throughout
the washout period and the first hour of the experimental period
contained calcium (5 mg/dl) and inorganic phosphorus (3.5 mg/
dl). It was equilibrated with a 95% oxygen, 5% carbon dioxide
gas mixture, and the pH was adjusted if necessary to 7.35 to
7.40 with sodium hydroxide. Several studies were carried out to
determine the effect of various metabolic inhibitors on the
phosphate effect. These inhibitors were given to the whole
animal either at a varying period before the study began or
added to a batch of the perfusate immediately prior to its use. In
preliminary experiments the perfusate also contained 10% heat-
treated rat serum, but when we found the change in cyclic AMP
production following the addition of PTH to the perfusate was
similar whether or not the rat serum was present, this was
subsequently omitted.
Individual experiments
(1) Response to parathyroid hormone. Tails were perfused
for 90 mm for baseline collections then the perfusion was
continued with fluid containing synthetic bovine PTH 1—34
fragment (Beckman Pharmaceuticals, Palo Alto, California), for
an additional 60 mm. Cyclic AMP concentration was measured
in each 10-mm sample. Similar studies were carried out using
tails from rats which had been given 75 1Ci of 45Ca 7 days prior
to use and the effect of PTH on 45Ca and stable calcium release
was noted.
(2) Effect of changing the perfusate phosphate concentration
on 45Ca release. All rats were given 75 pCi of 4tCa 7 days prior
to using the tails for an experiment. Samples of the effluent
were collected every 10 mm for either 2 or 3 hr. After I hr, the
concentration of phosphate in the perfusate was changed from
3.5 mg/dl inorganic phosphorus, to a range of concentrations
from zero to 10.5 mg/dl for the second hour. Calcium release
was determined by noting the amount of 45Ca appearing in the
effluent. To show that changes in the concentration of 45Ca in
the effluent actually reflected 45Ca release from bone, we took
five of the tail preparations at the end of the usual 2-hr washout
period, separated bone from soft tissue, and counted an aliquot
of an acid solution of the ashed tissues.
(3) The effect of phosphate on 45Ca deposition into bone. In
these studies rats were used that were not prelabelled with
45Ca, but instead 45Ca was added to the perfusate. In each tail a
bolus of 45Ca (approximately 50,000 cpm) was added to the
perfusate after the washout was completed, and then a second
bolus was added 90 mm later. These maneuvers were carried
out in one group of tails where the phosphorus concentration
was kept constant at 3.5 mg/dl and in another group where the
concentration was increased to 7 mg/dl immediately prior to the
second bolus. The amount of 45Ca appearing in the effluent after
each bolus was determined.
(4) Effect of change in phosphate concentration on PTH-
stimulated cyclic AMP production. To examine one possible
mechanism of the inhibitory action of phosphate on calcium
Fig. 1. Arrangement for in vitro perfusion of rut
tails. After systemic heparinization, the ventral
artery of the tail is cannulated with PE 50
tubing. Then the tail is removed from the animal
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Fig. 2. Effect of phosphate on calcium release. Amount of 45Ca in ix
effluent coming from rat tails perfused with an aqueous Krebs ringer
bicarbonate solution which was gassed with 95% oxygen, and 5%
carbon dioxide. In one group the phosphate concentration was kept
constantat 3.5 mg/dl, and in the other it was increased to 7 mg/dl during
the second hour of the experiment. Percentages are means + SEM.
release, we studied baseline and PTH-stimulated cyclic AMP
production in two groups of tails. One group was perfused with
3.5 mg/dl phosphorus solution throughout the experiment; in
the other group the phosphorus was increased to 7 mg/dl after
the first 60 mm. Collection of effluent for cyclic AMP concen-
tration began in both groups 70 mm after the washout period
had finished. After two baseline collection periods, perfusate
containing bovine PTH 1—34 fragment 100 ng/ml was used for 5
mm. The effluent was collected for a further 25 mm at 5-mm
intervals.
(5) Studies to observe whether or not the modulation of cell
metabolism would affect the action of phosphate on 45Ca
release. In these experiments cell function was perturbed by
five different mechanisms. In each instance we measured the
concentration of 45Ca in each 10-mm sample of the effluent, and
the concentration of lactate in the tenth 10-mm sample. Two
groups were compared: One group was perfused with a solution
containing 3.5 mg/dl inorganic phosphorus for 2 hr, the other
with a solution containing 3.5 mg/dl for the first, and 7 mg/dl for
the second hour, The five mechanisms were as follows: (a) The
perfusate was cooled to 40 C during the 2-hr washout period and
during the experiment. (b) The 95% oxygen, 5% carbon dioxide
gas mixture used to equilibrate the perfusate was replaced with
a 95% nitrogen, 5% carbon dioxide mixture for the washout and
the experimental period. (c) lodoacetate was added to the
perfusate in a concentration of 1 m for the last 30 mm of the
washout period and the 2-hr experimental period. (d) Rats were
given Actinomycin D intraperitoneally in a dose of 100 tg/l00 g
16 hr prior to removal of the tail. (e) Rats were given coichicine
in a dose of 0.2 mgIlOO g 3 hr prior to removal of the tail.
(6) Effect of changing the perfiisate phosphate concentration
on distribution of flow between bone and soft tissue. Two
groups of tails were used and the phosphorus concentration was
changed exactly as described in the fifth experiment. At the
completion of the second hour the distribution of flow of
perfusate between bone and soft tissue was determined. A 0.2
ml bolus of perfusate containing 15-p diameter microspheres
labeled with 85Sr (3M Company, St. Paul, Minnesota) was
injected into the tail via a three-way tap situated close to the site
0 2.5 5.0 7.5 10.0
Phosphorous concentration of perfu sate, mg/dI
Fig. 3. Effect of increasing the perfusate phosphate on 45Ca release.
The figure summarizes a series of experiments showing the effect of
changing the phosphate concentration of the perfusate on the mean 45Ca
activity present in the effluent during the final three collection periods
(30 mm). The abscissa shows the phosphate concentration used in the
final 60 mm of the experiment; N = the number of rats in each group.
where the catheter entered the tail artery. The tail was perfused
for a further 5 mm, the cannula was removed, and the proximal
one third of the tail was counted in a gamma well counter. The
soft tissue was separated from the bone and then each portion
was counted separately to determine the distribution of the
microspheres. Radioactive microspheres were chosen as an
indicator of bone blood flow because a recent report suggested
that there are few theoretical objections to this technique [18].
Biochemical methods
The methods for determination of calcium and phosphorus
concentration in fluids have been described previously [191;
45Ca in the perfusate was measured by counting 0.5 ml in 10 ml
of "Aquasol" (New England Nuclear, Massachusetts). When
45Ca was determined in tissues, the ash was dissolved in 6 N
hydrochloric acid, and an aliquot of this was counted in
"Aquasol II." Scintillation counting was carried out in a Searle
Mark III liquid scintillation counter. Gamma counting was done
in a well type gamma counter (Nuclear Chicago, Chicago,
Illinois). Lactate was measured using a UV method (Boeh-
ringer-Mannheim, West Germany) and cyclic AMP using a kit
method (Sigma Chemical Co., St. Louis, Missouri).
All results are expressed as mean SEM, and where indicat-
ed, Student's t test for unpaired samples were used to deter-
mine the difference between the means of two groups.
Results
(I) Response to parathyroid hormone. In a typical experi-
ment the baseline cyclic AMP concentration of the effluent was
0.5 0.01 pmole/ml (nine 10-mm collections) and 2.76 0.02
pmole/ml during the presence of PTH, (six 10-mm collection
periods). This difference was highly significant (P <0.001). No
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Fig. 4. Effect of phosphate on 45Ca retention. This figure shows the
percentage of a bolus of 45Ca, added to the perfusate, which was
recovered from the effluent in a subsequent 90-mm period. The proce-
dure was then repeated during the same perfusion but in half the tails
the phosphate concentration was increased to 7 mgldl.
of the effluent was noted following the addition of PTH to the
perfusate for up to 2 hr.
(2) Effect of changing perfusate phosphate concentration on
45Ca release. In the experiments to demonstrate that changes in
45Ca in the effluent reflected events happening in bone, we
found that 95.1 1.2% (N = 5) of the total counts in the tail
were present in the bone fraction. Figure 2 shows the results of
the experiment lasting 3 hr. Because there was some variation
from tail to tail in the initial radioactivity of the effluent, the
mean radioactivity (CPM/ml) of the first two samples was taken
as 100%. All subsequent results for that particular tail were
expressed as a percentage of this initial mean value. This
method of expressing the 45Ca concentration in the effluent
was used for all experiments involving 45Ca release. There was
a decrease in effluent radioactivity when the perfusate phos-
phate was increased to 7 mg/dl indicating that phosphorus is
inhibiting 45Ca release from the bone. Thirty minutes after the
phosphorus concentration was increased, the difference in 45Ca
in the effluent between the two groups was highly significant
P < 0.005. This difference continued to increase during the next
two collection periods.
A series of similar experiments were carried out using a range
of different phosphate concentrations during the second hour of
the experiment. Results of these experiments including the two
described above are shown in Figure 3. There was significantly
less 45Ca in the effluent during the final 30 mm in the group
perfused with 4.375 mg/dl phosphorus solution compared with
the 3.5 mg/dl group (P < 0.02). With a further increase in
phosphorus to 5.25 mg/dl, the difference between this group and
the 3.5 mgldl group was more marked (P < 0.001). However,
further increases in the phosphorus concentration of the perfus-
ate to 7.0 and 10.5 mg/dl did not further depress the 45Ca
release.
(3) Effect of phosphorus on 45Ca deposition into bone. The
results shown in Figures 2 and 3 do not indicate whether or not
an increase in phosphorus causes an increased deposition of
45Ca into bone. To investigate this point 45Ca was added to the
perfusate rather than being given to the rats 1 week before. The
results are shown in Figure 4; in group 1 87.0% 2.0% of the
second bolus was recovered compared with 89.1% 1.9% of
the second bolus in group 2. There was no statistical difference
between these two recoveries: P > 0.4. Thus, these experi-
ments suggest that raising the perfusate phosphorus concentra-
tion does not increase 45Ca retention by the tail bones.
(4) Effect of change in phosphorus concentration on PTH-
stimulated cyclic AMP production. The results in FigureS show
that there was no inhibition of either the baseline or PTH-
stimulated cyclic AMP production by the higher phosphate
perfusate. In fact a trend to more cyclic AMP production, both
baseline and PTH-stimulated, in the higher phosphate group
was noted. The increase was 7.7 1.0 times baseline in the 3.5
mg/dl group and 9.9 2.8 in the 7 mg/dl group. This trend was
more obvious when the total amount of cyclic AMP produced
after the PTH was calculated. In the low phosphorus group 9.6
2.3 pmoles and in the high phosphorus group 18.8 3.3
pmoles were produced. The difference between these values
was not significant (t = 2.02, N = 5) although it is possible that
with larger numbers a real increase in cyclic AMP production
might be seen with the higher perfusate phosphate.
(5) Studies to show whether or not modulation of cell metab-
olism would affect the action of phosphorus on 45Ca release. (a)
Effect of cooling the perfusate to 4°C. These results are shown
in Figures 6 and 7. It can be seen that this maneuver abolished
the difference in 45Ca release seen in Figure 2 between the 3.5
and 7 mg/dl groups. This suggests that cell metabolism is
important for the phosphorus effect. Evidence for inhibition of
cell metabolism is shown by the finding of very low lactate
concentration in the effluent (Fig. 7). (b) Perfusion under
anerobic conditions and (c) with iodoacetate in the perfusate.
Both of these maneuvers abolished the difference between the
3.5 and 7 mg!dl groups, P>0.2 and >0.1, respectively (Fig. 7).
As expected, the iodoacetate inhibited lactate production but
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Fig. 5. Cyclic AMP production by rat tails. The figure demonstrates an
effect of a low and high phosphate perfusate on baseline and PTH-
stimulated cyclic AMP production. At 20 mm after time = 0, perfusate
containing PTH, 1-34 fragment (100 ng/ml) was used for 5 mm. Five tails
were in each group.
I I0 10 20 30 40 50
Time, rn/n
Perfuse Rats given
at 4 C actinornycin 0
Anaerobic 1MM lodoacet Ratagiven
Treatment NIL N2 perfute in perfute coichicine
No. 88 55 65 68 55 67
100
a)
Pi mgdI 3.5 7.0 3.5 7.0 3.5 7.0 3.5 7.0 3.5 7.0
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mean plasma calcium immediately prior to tail removal in rats
treated with this substance was 8.3 0.7 mg/dl (N = 10),
significantly lower than the normal plasma calcium of 11.4 0.5
mg/dl (N = 6), P < 0.02. There was no difference between the
low and high phosphate groups (Fig. 7) although lactate produc-
tion was not inhibited. (e) Coichicine, in contrast to actinomy-
cm D did not abolish the phosphate effect. There was a
significant difference between 3.5 and 7 mg/dl groups; P value
was < 0.005. This dose of colchicine resulted in a mean plasma
calcium immediately prior to tail removal, of 8.8 0.2 mg/dl (N
= 13) indicating a definite effect on calcium metabolism.
(6) Effect of changing the perfusate phosphate concentration
on distribution of flow between bone and soft tissue. In the
group perfused with 3.5 mg/dl phosphorus solution the amount
of 85Sr in the bone was expressed as a percentage of total 85Sr in
the segment of tail examined (proximal one third) and was 55.8
4.7%, N = 8. This was not significantly different from the
percentage radioactivity (57.5 4.7%, N = 7) in the bone of the
tail perfused with the 7 mg/dl phosphorus solution. These
results suggest that the higher phosphate perfusion does not
alter the flow of perfusate to the bone and therefore must be
inhibiting 45Ca release by a more direct effect on calcium
release.
Discussion
In previous work from this laboratory we have shown that
resistance to the calcemic action of parathyroid hormone in rats
with acute renal failure, is caused by phosphate retention [201.
We further investigated this phosphate effect in vivo in rats, and
we have shown that phosphate infusions inhibit parathyroid
action either by increasing Ca deposition into bone or by
inhibiting calcium removal from bone. In these studies (unpub-
lished) soft tissue calcification did not appear to account for the
inhibition of parathyroid action.
Lactate conc 5.10 1.19 3.79 0.71 0.50 0.03 1.50 0.08 8.4 1.2 6.35 0.6
mg/dl (no.) 9 10 7 14 2 11
Fig. 7. Effect of inhibitors of metabolism on 45Ca release. The figure
represents the results of a series of studies using rat tails perfused with
either 3.5 mgldl or 7 mg/dl phosphorus solutions. Either the perfusate or
the rat was treated in such a manner as to alter cell metabolism. The
columns show the amount of 45Ca present in the effluent collected
during the last 30 mm. The lactate is the concentration measured in the
effluent at the beginning of this 30-mm period.
The present studies were designed to examine the effect of
phosphate on calcium movement in and out of bone in an in
vitro model and to determine, if possible, the mechanism of the
phosphate effect. In preliminary studies with this tail perfusion
system, we showed that the tissue remained viable during the
period of experimentation by demonstrating the presence of
protein synthesis and a constant rate of lactate production. In
addition, the bone responded appropriately to the presence of
the 1-34 fragment of PTH in the perfusate by producing a
several fold increase in the amount of cyclic AMP in the
effluent. We were unable, however, to demonstrate an effect of
PTH on 45Ca or stable calcium release possibly because this
action of PTH requires a much longer time for an effect to take
place.
In this model we were able to show definite inhibition of 45Ca
release as the phosphorus concentration was increased (Figs. 2
and 3). Surprisingly, this effect was demonstrated over quite a
narrow range of phosphorus concentrations, somewhat below
the usual extracellular fluid concentration of this anion found in
the rat. This suggested that the mechanism is more likely to be a
metabolic one rather than being a simple physico-chemical
effect. There seems little doubt that the phosphorus is actually
inhibiting 45Ca release from bone in this particular model
considering we demonstrated that more than 95% of the 45Ca
present in the tail at the beginning of the experiment was
associated with the bone rather than the soft tissue component
of the tail.
Another interpretation of Figure 3 could be that reduction of
the perfusate phosphorus from 5.25 to 3.0 mg/dl is stimulating





















Fig. 6. Effect of cooling. Rat tails were perfused at 4 C, and the effect
of an increase in perfusate phosphate concentration (during the experi-
mental period) on 45Ca released into the effluent was noted.
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plasma inorganic phosphorus level is taken into account. How-
ever, because this is an in vitro system using an aqueous
perfusate and because we chose to use a concentration of 3.5
mgldl for the washout and control periods, it would seem
reasonable to view the increase in phosphate perfusate as
inhibiting calcium release.
In these studies we were unable to demonstrate that increas-
ing the perfusate phosphate concentration caused an increase in
45Ca uptake by bone (Fig. 4). Thus, at least in this model
phosphate does not seem to have a mineralizing action. Howev-
er, it is possible that the high perfusate flow rate may prevent
subtle changes in 45Ca concentration in the effluent from being
noted. Although most of the more acute studies published [13,
16, 171 do not show an effect of phosphate on inhibiting bone
resorption. An earlier study by Raisz et al [15] gives support to
our findings that, at least under certain circumstances, phos-
phate will inhibit calcium release from bone. Long-term studies
show phosphorus usually causes bone resorption, but this is
secondary to parathyroid stimulation [9, 22, 23].
It was clear that the effect of phosphate on 45Ca release is due
to an effect on cell function rather than being due to physico-
chemical precipitation of phosphate-45Ca complexes at the bone
surface because the three nonspecific inhibitors of cell function,
cooling, anoxia, and iodoacetate all abolished the phosphate
effect (Fig. 7). In addition, the phosphorus effect is not due to
inhibition of cyclic AMP production (Fig. 5).
Interpretation of the results of experiments using actinomy-
cm D and colchicine was more difficult. Both of these agents
produced a similar degree of hypocalcemia but resulted in
different effects in the in vitro preparation. Actinomycin D
abolished the difference in 45Ca release between the high and
low phosphate groups, but colchicine had no effect (Fig. 7).
Although there have been relatively few publications on the
effect of actinomycin D on bone and calcium metabolism [25—
27], it appears that its mechanism of action at the molecular
level is similar to mithramycin [281. This latter substance is
thought to act by inhibiting bone resorption [29, 30] at the
cellular level, and it is known to be a potent inhibitor of RNA
synthesis [31]. That actinomycin D should inhibit the effect of
phosphate, which itself appears to be inhibiting bone resorption
or at least 45Ca release, was a little surprising, however, Minkin
[29] has shown that mithramycin inhibits bone formation as well
as resorption and suggests that the cytotoxic action is not
specific for osteoclasts and that all bone cells may be involved.
Thus, this result also may be taken as evidence that the
inhibitory effect of phosphate is dependent on cellular activity.
When we studied the effect of colchicine, we found that this
substance did not block the phosphate effect. This was unex-
pected because as well as actinomycin D, colchicine has been
shown to inhibit parathyroid action [321 and more recently, to
inhibit bone resorption in tissue culture [33]. The difference
may be explained by the fact that these two agents have
different mechanisms of action. Colchicine is thought to inhibit
bone resorption by its effect on microtubular function [33]. A
simpler explanation could be that the colchicine effect was
removed during the washout period whereas effect of the
actinomycin D was not removed. Therefore, at this point, we
are unable to state which cells are involved in the phosphate
effect and we cannot usefully speculate in detail on its
mechanism.
In summary, we have devised an in vitro bone perfusion
model using rat tails, and in this model we have demonstrated
that raising the concentration of phosphate in the perfusing
solution inhibits 45Ca release from bone. We also demonstrated
that this phosphate effect depends on some aspect of cell
function, but it does not involve inhibition of cyclic AMP
production. We were unable to find any evidence for an effect
of raising the phosphate concentration on increasing calcium
deposition into bone.
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